Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39750
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFelicetti P.en
dc.contributor.authorChandler R.en
dc.contributor.authorGirolomoni G.en
dc.contributor.authorHadden R.D.M.en
dc.contributor.authorKochar S.en
dc.contributor.authorKucuku M.en
dc.contributor.authorMonaco G.en
dc.contributor.authorOzen S.en
dc.contributor.authorPahud B.en
dc.contributor.authorPhuong L.en
dc.contributor.authorBachtiar N.S.en
dc.contributor.authorTeeba A.en
dc.contributor.authorTop K.en
dc.contributor.authorVarricchio F.en
dc.contributor.authorWise R.P.en
dc.contributor.authorZanoni G.en
dc.contributor.authorZivkovic S.en
dc.contributor.authorBonhoeffer J.en
dc.contributor.authorBurgner D.en
dc.contributor.authorBrauchli Pernus Y.en
dc.contributor.authorSantuccio C.en
dc.contributor.authorBonetto C.en
dc.contributor.authorTrotta F.en
dc.date.accessioned2021-05-14T13:35:02Zen
dc.date.available2021-05-14T13:35:02Zen
dc.date.copyright2016en
dc.date.created20161214en
dc.date.issued2016-12-14en
dc.identifier.citationVaccine. 34 (51) (pp 6634-6640), 2016. Date of Publication: 12 Dec 2016.en
dc.identifier.issn0264-410Xen
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/39750en
dc.description.abstractBackground Vasculitides have been reported as adverse events following immunization (AEFI) following various vaccines. We describe reports of vasculitis to three international spontaneous reporting systems. Methods All spontaneous reports of vasculitis following immunization between January 2003 and June 2014 were retrieved from Eudravigilance (EV), the Vaccine Adverse Event Reporting System (VAERS), and VigiBase. A Standard MedDRA Query (SMQ) for vasculitis was used and vaccine types were categorized using the Anatomical Therapeutic Chemical classification system. We performed a descriptive analysis by source, sex, age, country, time to onset, vaccine, and type of vasculitis. Results We retrieved 1797 reports of vasculitis in EV, 1171 in VAERS, and 2606 in VigiBase. Vasculitis was predominantly reported in children aged 1-17 years, and less frequently in the elderly (>65 years). The generic term "vasculitis" was the most frequently reported AEFI in this category across the three databases (range 21.9% to 27.5% of all reported vasculitis for vaccines). For the more specific terms, Henoch-Schoenlein Purpura (HSP) was most frequently reported, (19.1% on average), followed by Kawasaki disease (KD) (16.1% on average) and polymyalgia rheumatica (PMR) (9.2% on average). Less frequently reported subtypes were cutaneous vasculitis (CuV), vasculitis of the central nervous system (CNS-V), and Behcet's syndrome (BS). HSP, PMR and CuV were more frequently reported with influenza vaccines: on average in 29.3% for HSP reports, 61.5% for PMR reports and in 39.2% for CuV reports. KD was reported with pneumococcal vaccines in 32.0% of KD reports and with rotavirus vaccines in more than 20% of KD reports. BS was most frequently reported after hepatitis and HPV vaccines and CNS-V after HPV vaccines. Conclusion Similar reporting patterns of vasculitides were observed in different databases. Implementation of standardized case definitions for specific vasculitides could improve overall data quality and comparability of reports.Copyright © 2015en
dc.languageEnglishen
dc.languageenen
dc.publisherElsevier Ltden
dc.relation.ispartofVaccineen
dc.titleSpontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.vaccine.2015.09.027en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid26392009 [http://www.ncbi.nlm.nih.gov/pubmed/?term=26392009]en
dc.identifier.source613550386en
dc.identifier.institution(Felicetti, Trotta, Bonetto, Santuccio) Italian Medicines Agency, Rome, Italy (Brauchli Pernus, Bonhoeffer) Brighton Collaboration Foundation, Basel, Switzerland (Burgner) Monash Children's Hospital-Clayton, Melbourne, Australia (Burgner) Murdoch Children's Research Institute (MCRI) - Department of Paediatrics, Melbourne University, Australia (Chandler) Uppsala Monitoring Centre, Uppsala, Sweden (Girolomoni) University of Verona, Department of Medicine, Section of Dermatology and Venereology, Verona, Italy (Hadden) King's College Hospital, London, United Kingdom (Kochar) USAID, Deliver Project, JSIPL, New Delhi, India (Kucuku) Department of Vaccines Control, National Agency for Medicine & Medical Devices, Tirana, Albania (Monaco) Centre for Pharmacovigilance, The Lombardy Region, Milan, Italy (Ozen) Hacettepe University, Department of Pediatric Rheumatology, Ankara, Turkey (Pahud) Children's Mercy Hospital, Kansas City, MO, United States (Phuong) Monash Children's and Royal Children's Hospitals, Melbourne, Australia (Bachtiar) Bio Farma Vaccine Institute, Bandung, West Java, Indonesia (Teeba) Centre National Anti Poison et de Pharmacovigilance, Rabat, Morocco (Top) Department of Pediatrics, Dalhousie University, Halifax, NS, Canada (Varricchio) Independent Consultant Vaccinologist, Wakefield, RI, United States (Wise) MedImmune/AstraZeneca, Gaithersburg, MD, United States (Zanoni) Immunology Unit, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy (Zivkovic) University of Pittsburgh Medical Center and Neurology service, MSL, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States (Bonhoeffer) University of Basel Children's Hospital, Basel, Switzerlanden
dc.description.addressP. Felicetti, Italian Medicines Agency, Rome, Italy. E-mail: contact@brightoncollaboration.orgen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2017 Elsevier B.V., All rights reserved.en
dc.subect.keywordsAdverse event following immunization (AEFI) Eudravigilance Immunization Pharmacovigilance Spontaneous reporting Vaccines VAERS Vasculitis VigiBaseen
dc.identifier.authoremailFelicetti P.; contact@brightoncollaboration.orgen
dc.description.grantOrganization: (AIFA) *Agenzia Italiana del Farmaco, Ministero della Salute* Country: Italyen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:Articles
Show simple item record

Page view(s)

16
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.